Product Description
ASN100 is a novel antibody combination of two fully human IgG1(_) monoclonal antibodies (MAbs), ASN-1 and ASN-2, which neutralize sixStaphylococcus aureuscytotoxins, alpha-hemolysin (Hla) and five bicomponent leukocidins.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: X4
Company Location: BOSTON MA 02134
Company CEO: Paula Ragan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Pneumonia, Ventilator-Associated|Pneumonia, Staphylococcal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ASN100-201 | P2 |
Terminated |
Pneumonia, Staphylococcal|Pneumonia, Ventilator-Associated |
2018-07-19 |